Age at Treatment=64.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.67;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.67;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.67;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.67;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.67;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.67;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.67;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.67;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.67;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.67;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.67;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.67;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.67;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=64.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.67;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.53;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.53;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.53;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=5.53;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.53;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.53;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.53;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.53;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.53;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.53;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.53;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.53;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.53;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.53;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.53;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=51.8;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=5.53;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.49;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.49;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.49;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.49;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.49;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.49;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.49;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.49;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.49;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.49;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.49;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.49;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.49;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.49;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=60.0;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.49;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.52;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.52;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.52;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.52;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Gleason Score=3+4;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Gleason Score=3+4;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Gleason Score=3+4;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Gleason Score=3+4;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Gleason Score=3+4;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Gleason Score=3+4;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Gleason Score=3+4;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Gleason Score=3+4;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Gleason Score=3+4;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Gleason Score=3+4;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Gleason Score=3+4;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=57.4;Gender=M;Gleason Score=3+4;Pathology T=T2b;Phenotype=OBI_0000922;PreTreatment PSA=6.52;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.88;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.88;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=4.88;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;Gender=M;Gleason Score=4+3;Pathology T=T3b;Phenotype=OBI_0000922;PreTreatment PSA=4.88;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.15;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.15;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.15;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.15;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.15;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.15;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.15;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.15;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.15;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.15;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.15;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.15;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.15;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=71.6;Gender=M;Gleason Score=3+4;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=8.15;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.63;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.63;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.63;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.63;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.63;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.63;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.63;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.63;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.63;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.63;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.63;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=70.3;Gender=M;Gleason Score=4+3;Pathology T=T3a;Phenotype=OBI_0000922;PreTreatment PSA=4.63;Tissue=Prostate Tumour;ENA-CHECKLIST=ERC000026;
Age at Treatment=73.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.0;Sample=CPCG0030-B1;Tissue=Blood;donor_id=CPCG0030;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.96;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.96;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=66.2;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=6.96;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.65;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.65;Tissue=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=58.1;Gender=M;Phenotype=OBI_0000747;PreTreatment PSA=8.65;Tissue=Blood;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0103;gender=male;Germline BRCA Status=WT;phenotype=Prostate Cancer;Sample=CPCG0103-B1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Blood;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0103;gender=male;Germline BRCA Status=WT;phenotype=Prostate Cancer;Sample=CPCG0103-B1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Blood;ENA-CHECKLIST=ERC000026;
donor_id=CPCG0103;gender=male;Germline BRCA Status=WT;phenotype=Prostate Cancer;Sample=CPCG0103-B1;Tissue Source=UHN-Toronto,Canada;Tissue Type=Blood;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.4;gender=male;phenotype=OBI_0000747;PreTreatment PSA=13.0;Sample=CPCG0187-B1;Tissue=Blood;donor_id=CPCG0187;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.4;gender=male;phenotype=OBI_0000747;PreTreatment PSA=13.0;Sample=CPCG0187-B1;Tissue=Blood;donor_id=CPCG0187;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.4;gender=male;phenotype=OBI_0000747;PreTreatment PSA=13.0;Sample=CPCG0187-B1;Tissue=Blood;donor_id=CPCG0187;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.4;gender=male;phenotype=OBI_0000747;PreTreatment PSA=13.0;Sample=CPCG0187-B1;Tissue=Blood;donor_id=CPCG0187;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.4;gender=male;phenotype=OBI_0000747;PreTreatment PSA=13.0;Sample=CPCG0187-B1;Tissue=Blood;donor_id=CPCG0187;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.4;gender=male;phenotype=OBI_0000747;PreTreatment PSA=13.0;Sample=CPCG0187-B1;Tissue=Blood;donor_id=CPCG0187;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.4;gender=male;phenotype=OBI_0000747;PreTreatment PSA=13.0;Sample=CPCG0187-B1;Tissue=Blood;donor_id=CPCG0187;ENA-CHECKLIST=ERC000026;
Age at Treatment=72.4;gender=male;phenotype=OBI_0000747;PreTreatment PSA=13.0;Sample=CPCG0187-B1;Tissue=Blood;donor_id=CPCG0187;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.7;Sample=CPCG0194-B1;Tissue=Blood;donor_id=CPCG0194;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.7;Sample=CPCG0194-B1;Tissue=Blood;donor_id=CPCG0194;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.7;Sample=CPCG0194-B1;Tissue=Blood;donor_id=CPCG0194;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.7;Sample=CPCG0194-B1;Tissue=Blood;donor_id=CPCG0194;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.7;Sample=CPCG0194-B1;Tissue=Blood;donor_id=CPCG0194;ENA-CHECKLIST=ERC000026;
Age at Treatment=69.8;gender=male;phenotype=OBI_0000747;PreTreatment PSA=8.7;Sample=CPCG0194-B1;Tissue=Blood;donor_id=CPCG0194;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.9;Sample=CPCG0451-B1;Tissue=Blood;donor_id=CPCG0451;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.9;Sample=CPCG0451-B1;Tissue=Blood;donor_id=CPCG0451;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.9;Sample=CPCG0451-B1;Tissue=Blood;donor_id=CPCG0451;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.9;Sample=CPCG0451-B1;Tissue=Blood;donor_id=CPCG0451;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.9;Sample=CPCG0451-B1;Tissue=Blood;donor_id=CPCG0451;ENA-CHECKLIST=ERC000026;
Age at Treatment=61.6;gender=male;phenotype=OBI_0000747;PreTreatment PSA=7.9;Sample=CPCG0451-B1;Tissue=Blood;donor_id=CPCG0451;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.1;Sample=CPCG0452-B1;Tissue=Blood;donor_id=CPCG0452;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.1;Sample=CPCG0452-B1;Tissue=Blood;donor_id=CPCG0452;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.1;Sample=CPCG0452-B1;Tissue=Blood;donor_id=CPCG0452;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.1;Sample=CPCG0452-B1;Tissue=Blood;donor_id=CPCG0452;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.1;Sample=CPCG0452-B1;Tissue=Blood;donor_id=CPCG0452;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.1;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.1;Sample=CPCG0452-B1;Tissue=Blood;donor_id=CPCG0452;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.2;Sample=CPCG0454-B1;Tissue=Blood;donor_id=CPCG0454;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.2;Sample=CPCG0454-B1;Tissue=Blood;donor_id=CPCG0454;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.2;Sample=CPCG0454-B1;Tissue=Blood;donor_id=CPCG0454;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.2;Sample=CPCG0454-B1;Tissue=Blood;donor_id=CPCG0454;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.2;Sample=CPCG0454-B1;Tissue=Blood;donor_id=CPCG0454;ENA-CHECKLIST=ERC000026;
Age at Treatment=52.5;gender=male;phenotype=OBI_0000747;PreTreatment PSA=9.2;Sample=CPCG0454-B1;Tissue=Blood;donor_id=CPCG0454;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.6;Sample=CPCG0474-B1;Tissue=Blood;donor_id=CPCG0474;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.6;Sample=CPCG0474-B1;Tissue=Blood;donor_id=CPCG0474;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.6;Sample=CPCG0474-B1;Tissue=Blood;donor_id=CPCG0474;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.6;Sample=CPCG0474-B1;Tissue=Blood;donor_id=CPCG0474;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.6;Sample=CPCG0474-B1;Tissue=Blood;donor_id=CPCG0474;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.6;Sample=CPCG0474-B1;Tissue=Blood;donor_id=CPCG0474;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.6;Sample=CPCG0474-B1;Tissue=Blood;donor_id=CPCG0474;ENA-CHECKLIST=ERC000026;
Age at Treatment=56.9;gender=male;phenotype=OBI_0000922;PreTreatment PSA=4.6;Sample=CPCG0474-B1;Tissue=Blood;donor_id=CPCG0474;ENA-CHECKLIST=ERC000026;
